China Rare Disease Genetic Testing Market Size & Outlook

The rare disease genetic testing market in China is expected to reach a projected revenue of US$ 94.5 million by 2028. A compound annual growth rate of 11% is expected of China rare disease genetic testing market from 2021 to 2028.
Revenue, 2020 (US$M)
$41.1
Forecast, 2028 (US$M)
$94.5
CAGR, 2021 - 2028
11%
Report Coverage
China

China rare disease genetic testing market highlights

  • The China rare disease genetic testing market generated a revenue of USD 41.1 million in 2020 and is expected to reach USD 94.5 million by 2028.
  • The China market is expected to grow at a CAGR of 11% from 2021 to 2028.
  • In terms of segment, neurological disorders was the largest revenue generating disease type in 2020.
  • Cancer is the most lucrative disease type segment registering the fastest growth during the forecast period.


Rare disease genetic testing market data book summary

Market revenue in 2020USD 41.1 million
Market revenue in 2028USD 94.5 million
Growth rate11% (CAGR from 2020 to 2028)
Largest segmentNeurological disorders
Fastest growing segmentCancer
Historical data2016 - 2019
Base year2020
Forecast period2021 - 2028
Quantitative unitsRevenue in USD million
Market segmentationNeurological Disorders, Immunological Disorders, Hematology Diseases, Endocrine & Metabolism Diseases, Cancer, Musculoskeletal Disorders, Cardiovascular Disorders, Dermatology Disease
Key market players worldwideQuest Diagnostics Inc, Centogene NV Ordinary Shares, Invitae Corp, Eurofins Scientific SE, PerkinElmer, Macrogenics Inc, Fulgent Genetics Inc, Myriad Genetics Inc, Labcorp Holdings Inc, OPKO Health Inc, 3billion, ARUP Laboratories, Strand Life Sciences, Ambry Genetics, REALM IDx, Inc., Baylor Genetics, Health Network Laboratories, PreventionGenetics, Biora Therapeutics, CooperSurgical, Artemis DNA


Other key industry trends

  • In terms of revenue, China accounted for 5.3% of the global rare disease genetic testing market in 2020.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2028.
  • In Asia Pacific, China rare disease genetic testing market is projected to lead the regional market in terms of revenue in 2028.
  • India is the fastest growing regional market in Asia Pacific and is projected to reach USD 43.0 million by 2028.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Rare Disease Genetic Testing Market Companies

Name Profile # Employees HQ Website

China rare disease genetic testing market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to rare disease genetic testing market will help companies and investors design strategic landscapes.


Neurological disorders was the largest segment with a revenue share of 16.06% in 2020. Horizon Databook has segmented the China rare disease genetic testing market based on neurological disorders, immunological disorders, hematology diseases, endocrine & metabolism diseases, cancer, musculoskeletal disorders, cardiovascular disorders, dermatology disease covering the revenue growth of each sub-segment from 2016 to 2028.


China’s attempts to shift attention of the of the healthcare system towards diagnosis and treatment of rare diseases remained at the nascent stage. It is estimated that around 20 million individual are living with a rare condition in the country.

As a result, the government has included rare disease management as a public health priority in its 2030 roadmap titled Healthy China 2030. Furthermore, in June 2018, China released its first list of rare diseases in order to enable the patients to find solutions effectively at their local hospitals. In addition.

in February 2019, China announced to establish a national collaborative network of hospitals which would be devoted for diagnosis including early detection and treatment of rare disease diagnosis. This is expected to benefit the diagnostic developers operating in the country over the forecast period.

Reasons to subscribe to China rare disease genetic testing market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of China rare disease genetic testing market databook

  • Our clientele includes a mix of rare disease genetic testing market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the China rare disease genetic testing market , including forecasts for subscribers. This country databook contains high-level insights into China rare disease genetic testing market from 2016 to 2028, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

China rare disease genetic testing market

China Rare Disease Genetic Testing Market Outlook Share, 2020 & 2028 (US$M)

China rare disease genetic testing market

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more